Vascular injury involves the overoxidation of peroxiredoxin type II and is recovered by the peroxiredoxin activity mimetic that induces reendothelialization

Circulation

Volumn 128, Issue 8, 2013, Pages 834-844

  Kang, Dong Hoon ^a   Lee, Doo Jae ^a   Kim, Jiran ^a   Lee, Joo Young ^a   Kim, Hyun Woo ^d   Kwon, Kihwan ^c   Taylor, W Robert ^e   Jo, Hanjoong ^f   Kang, Sang Won ^a,b  

^a Division of Life and Pharmaceutical Sciences   (South Korea)

^b Department of Life Science ^*  (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

coronary restenosis; endothelium; peroxiredoxins; reactive oxygen species; receptor protein tyrosine kinases

Indexed keywords

HYDROGEN PEROXIDE; PEROXIDASE; PEROXIREDOXIN 2; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INJURY; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NEOINTIMA; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

CORONARY RESTENOSIS; ENDOTHELIUM; PEROXIREDOXINS; REACTIVE OXYGEN SPECIES; RECEPTOR PROTEIN-TYROSINE KINASES;

ANIMALS; BIOMIMETIC MATERIALS; CAROTID ARTERY INJURIES; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; HYDROGEN PEROXIDE; HYPERPLASIA; MALE; MICE; MICE, KNOCKOUT; OXIDATION-REDUCTION; PEROXIREDOXINS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84882796396     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.001725     Document Type: Article

References (31)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451:914-918
2. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503-516
3. Fuchs AT, Kuehnl A, Pelisek J, Rolland PH, Mekkaoui C, Netz H, Nikol S. Inhibition of restenosis formation without compromising reendothelialization as a potential solution to thrombosis following angioplasty? Endothelium. 2008;15:85-92
4. Klocke R, Hasib L, Nikol S. Recently patented applications of homologous cellular and extracellular agents as therapeutics or targets for the prevention of restenosis post-Angioplasty. Recent Pat Cardiovasc Drug Discov. 2006;1:57-66
5. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling: In control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371
6. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22:1276-1312
7. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: Therapeutic implications. Trends Mol Med. 2005;11:571-578
8. Choi MH, Lee IK, Kim GW, Kim BU, Han YH, Yu DY, Park HS, Kim KY, Lee JS, Choi C, Bae YS, Lee BI, Rhee SG, Kang SW. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature. 2005;435:347-353
9. Kang DH, Lee DJ, Lee KW, Park YS, Lee JY, Lee SH, Koh YJ, Koh GY, Choi C, Yu DY, Kim J, Kang SW. Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell. 2011;44:545-558
10. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury, part I: Basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912-1916
11. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241
12. Lee TH, Kim SU, Yu SL, Kim SH, Park DS, Moon HB, Dho SH, Kwon KS, Kwon HJ, Han YH, Jeong S, Kang SW, Shin HS, Lee KK, Rhee SG, Yu DY. Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood. 2003;101:5033-5038
13. Woo HA, Kang SW, Kim HK, Yang KS, Chae HZ, Rhee SG. Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid: Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence. J Biol Chem. 2003;278:47361-47364
14. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of NOX family proteins in human atherosclerosis. Circulation. 2002;105:1429-1435
15. Gardiner DM, Waring P, Howlett BJ. The epipolythiodioxopiperazine (ETP) class of fungal toxins: Distribution, mode of action, functions and biosynthesis. Microbiology. 2005;151(pt 4):1021-1032
16. Choi HS, Shim JS, Kim JA, Kang SW, Kwon HJ. Discovery of gliotoxin as a new small molecule targeting thioredoxin redox system. Biochem Biophys Res Commun. 2007;359:523-528
17. Pahl HL, Krauss B, Schulze-Osthoff K, Decker T, Traenckner EB, Vogt M, Myers C, Parks T, Warring P, Mühlbacher A, Czernilofsky AP, Baeuerle PA. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med. 1996;183:1829-1840
18. Bernardo PH, Brasch N, Chai CL, Waring P. A novel redox mechanism for the glutathione-dependent reversible uptake of a fungal toxin in cells. J Biol Chem. 2003;278:46549-46555
19. Milo R, Jorgensen P, Moran U, Weber G, Springer M. BioNumbers: The database of key numbers in molecular and cell biology. Nucleic Acids Res. 2010;38(database issue):D750-D753
20. Chae HZ, Kim HJ, Kang SW, Rhee SG. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract. 1999;45:101-112
21. Nishida S, Yoshida LS, Shimoyama T, Nunoi H, Kobayashi T, Tsunawaki S. Fungal metabolite gliotoxin targets flavocytochrome b558 in the activation of the human neutrophil NADPH oxidase. Infect Immun. 2005;73:235-244
22. Serena C, Ortoneda M, Capilla J, Pastor FJ, Sutton DA, Rinaldi MG, Guarro J. In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob Agents Chemother. 2003;47:3161-3164
23. Cheeke PR. Endogenous toxins and mycotoxins in forage grasses and their effects on livestock. J Anim Sci. 1995;73:909-918
24. Moerman KL, Chai CL, Waring P. Evidence that the lichen-derived scabrosin esters target mitochondrial ATP synthase in P388D1 cells. Toxicol Appl Pharmacol. 2003;190:232-240
25. Vigushin DM, Mirsaidi N, Brooke G, Sun C, Pace P, Inman L, Moody CJ, Coombes RC. Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Med Oncol. 2004;21:21-30
26. Sutton P, Newcombe NR, Waring P, Müllbacher A. In vivo immunosuppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi. Infect Immun. 1994;62:1192-1198
27. Lee YM, Lim JH, Yoon H, Chun YS, Park JW. Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1α premRNA in mice and in vitro. Hepatology. 2011;53:171-180
28. Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. Chaetocin: A promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood. 2007; 109:2579-2588
29. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004;6:33-43
30. Tibodeau JD, Benson LM, Isham CR, Owen WG, Bible KC. The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid Redox Signal. 2009;11:1097-1106
31. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol. 2005;1:143-145